{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:45:28Z","timestamp":1794901528525,"version":"4.9.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Purpose:<\/jats:title>\n                    <jats:p>Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&amp;E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&amp;E was noninferior to late-start T&amp;E.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A randomized, open-label, Phase 3b\/4 study that included treatment-na\u00efve patients aged \u226550 years with the best-corrected visual acuity 73\u201325 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, W4, W8, and W16. At W16, patients were randomized 1:1 to early-start (2W interval adjustments) or late-start T&amp;E (8W intervals until W48 then 2W interval adjustments). Primary endpoint: the best-corrected visual acuity change from randomization to W104.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two-hundred seventy-one patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 (12.1; early-T&amp;E) and 61.3 (10.8; late-T&amp;E) letters. The mean (SD) best-corrected visual acuity change (W16\u2013104) was \u22122.1 (11.4) versus \u22120.4 (8.4) letters (early-T&amp;E vs. late-T&amp;E; least-squares mean difference: \u22122.0; 95% confidence interval: \u22124.75 to 0.71;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0162 for noninferior); +4.3 (13.4) versus +7.9 (11.9) letters (W0\u2013104). The mean (SD) number of injections was 12.0 (2.3) versus 13.0 (1.8). From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was \u2212161.6 (135.6)\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m and \u2212158.6 (125.1)\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m. The last injection interval (W104) was \u226512W for 47.2% and 51.9% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Outcomes were similar between patients with neovascular age-related macular degeneration treated with an intravitreal aflibercept early-T&amp;E or late-T&amp;E regimen after initial dosing, with one injection difference over 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT02581891 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02581891. Supplemental Digital Contents (files 1 http:\/\/links.lww.com\/IAE\/B419).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000003128","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T03:06:21Z","timestamp":1617073581000},"page":"1911-1920","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":97,"title":["EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"41","author":[{"given":"Paul","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hykin","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Midena","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Padova, Padova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Souied","sequence":"additional","affiliation":[{"name":"Department d'Ophtalmologie, H\u00f4pital Intercommunal de Creteil, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Allmeier","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care, AG, Pharmaceuticals, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lambrou","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care, AG, Pharmaceuticals, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department for Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ARIES study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2147\/OPTH.S145732","article-title":"Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update","volume":"11","author":"Patel","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000452929","article-title":"Outcomes when switching from a pro re nata regimen to a treat and extend regimen using aflibercept in neovascular age-related macular degeneration","volume":"236","author":"Giannakaki-Zimmermann","year":"2016","journal-title":"Ophthalmologica"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R13-20250609","first-page":"406","article-title":"Pharmacokinetics of free aflibercept in patients with neovascular age related macular degeneration","volume":"58","author":"Do","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajo.2014.05.025","article-title":"Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration","volume":"158","author":"Fauser","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","article-title":"Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times","volume":"100","author":"Fauser","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ajo.2019.01.005","article-title":"Extended (every 12 weeks or longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of VIEW trials","volume":"200","author":"Khurana","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40123-018-0139-5","article-title":"Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Evidence from a clinical setting","volume":"7","author":"Eleftheriadou","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2017.06.002","article-title":"Treat-and-Extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial","volume":"180","author":"DeCroos","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of Ranibizumab and Aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"}],"updated-by":[{"DOI":"10.1097\/iae.0000000000003560","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T12:01:48Z","timestamp":1749470508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003128"}},"subtitle":["The ARIES Study: A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003128","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}